BNP Paribas Financial Markets
RNTX

BNP Paribas Financial Markets’s Rein Therapeutics RNTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5
Closed -$73 – 4508
2019
Q3 		$73 Hold
5
– – ﹤0.01% 4457
2019
Q2 		$78 Hold
5
– – ﹤0.01% 4485
2019
Q1 		$187 Hold
5
– – ﹤0.01% 4205
2018
Q4 		$81 Hold
5
– – ﹤0.01% 4212
2018
Q3 		$264 Hold
5
– – ﹤0.01% 4361
2018
Q2 		$520 Sell
5
-44
-90% -$4.98K ﹤0.01% 4326
2018
Q1 		$8.01K Buy
49
+3
+7% +$535 ﹤0.01% 4031
2017
Q4 		$9.62K Buy
+46
New +$11K ﹤0.01% 4035

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
IWAG
Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return

BNP Paribas Financial Markets's RNTX Position: Q4 2019 in Review

BNP Paribas Financial Markets sold out of Rein Therapeutics (RNTX) in Q4 2019, closing a stake of 5 shares — an estimated $73 sold.

BNP Paribas Financial Markets first reported a position in RNTX in Q4 2017 and held it in 8 quarters. The position peaked at $9.62K in Q4 2017. 17 funds tracked by Wall St. Rank hold RNTX as of Q4 2019.

  • BNP Paribas Financial Markets reported no remaining Rein Therapeutics position as of Q4 2019 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 5 Rein Therapeutics shares in Q4 2019, an estimated $73.
  • BNP Paribas Financial Markets first reported a position in Rein Therapeutics in Q4 2017 and held it in 8 quarters.
  • BNP Paribas Financial Markets's Rein Therapeutics position peaked at $9.62K in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2019.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2019, filed 12 Feb 2020.